Vaxcyte IncPCVX
Price$56.90

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Net Income -$1.1BTTM through 30 Jun 2026
Free Cash Flow -$894.1MTTM through 30 Jun 2026

Margins

Current

Returns

-38.6%ROE
-33.9%ROA

Balance Sheet Health

Current Ratio5.72x
Cash & Equivalents$183.2M

Quality Metrics

Piotroski F-Score1 / 9
Earnings-Beat Rate0.0%

Multi-Year Trend

Diluted EPS-$7.63TTM
'20'21'22'23'24'25
FY2025: $-5.63

Dividend

No dividend

Capital Allocation

R&D Spend$1B

Segment Performance

SegmentRevenueYoYOutlook
Vaccine Development$0
View details

Focus remains on clinical trial progression of VAX-31 and VAX-24

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.